Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

Cardiology (Switzerland)

Volumn 87, Issue 6, 1996, Pages 458-468

  Corsini, Alberto ^a   Bernini, Franco ^b   Quarato, Pierangelo ^a   Donetti, Elena ^a   Losta, Stefano Bel ^a   Fumagalli, Remo ^a   Paoletti, Rodolfo ^a   Soma, V Maurizio R ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Cholesterol esterification; Farnesol; Geranylgeraniol; Macrophages; Mevalonate pathway; Migration; Proliferation; Smooth muscle cells

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; FARNESOL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVALONIC ACID; MEVINOLIN; SIMVASTATIN;

ARTERY MUSCLE; ARTERY WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL ESTERIFICATION; CHOLESTEROL SYNTHESIS; LIPID STORAGE; PRIORITY JOURNAL; RESTENOSIS;

EID: 0029737574     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000177139     Document Type: Article

References (77)

1. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993.362: 801-809.
2. Wissler RW: Update on the pathogenesis of atherosclerosis: Am J Med 1991:91(suppl IB): 1B-3S-1B-9S.
3. Havel RJ. Rapaport H: Management of primary hyperlipidemia. N Engl J Med 1995:332: 1491-1498.
4. National Cholesterol Education Program: Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994;89:1329-1359.
5. Neaton JD. Wentworth DF: Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: Overall findings and differences by age for 316.099 white men. Arch Intern Med 1992:152:56-63.
6. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Prevention Trial results: II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374.
7. Frick MH. Elo O. Haapa K. Hcinonen OP. Hcinsalmi P. Helo P. Huttuncn JK. Kaita-niemi P. Koskinen P. Manninen V, Maenpaa H. Malkonen M. Manttari M. Norola S. Pasternack A. Pikkaraincn J. Romo M. Sjoblom T. Nikkila EA: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipoproteincmia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
8. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994:344:1383-1389.
9. Brown BG, Zhao X-Q. Sacco DE, Albers JJ: Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-1791.
10. Jukcma JW. Bruschkc AVG, van Bovcn AJ. Reiber JHC. Bal ET, Zwindcrman AH. Jansen H. Boerma GJM. van Rappard FM. Lie KI: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995:91:2528-2540.
11. MAAS Investigators: Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 1994:544: 633-638.
12. Brown MS. Goldstein JL: Drugs used in the treatment of hyperlipoproteinemias: in Gilman AG. Rail TW. Nies AS. Taylor P (eds): The pharmacological basis of therapeutics. Oxford. Pcrgamon Press. 1991, pp 874-896.
13. Endo A: The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992:33:1569-1582.
14. Illingworth DR. Erkclens DW. Keller U, Thompson GR. Tikkancn MJ: Defined daily doses in relation to hypolipidemic efficacy of lovastatin, pravastatin and simvastatin. Lancet 1994:343:1554-1555.
15. Blum CB: Comparison of properties of four inhibitors of 3-hydroxv-3-methylglutaryl-coen-zyme A reductase. Am J Cardiol 1994:73 (suppl):3D-11D.
16. Alberts A. Chen J. Kuron G. et al: Mevinolin: A highly-potent competitive inhibitor of hy-droxy-mcthvlglutaryl-coenzyme A reductase and cholesterol-lowering agents. Proc Natl Acad Sci USA 1980:77:3957-3961.
17. Tsujita Y. Kuroda M, and Shintada Y: CS-514, a competitive inhibitor of 3-hvdroxy-3-methyl-glutaryl coenzimc A reductase: Tissue selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim BiophysActa 1986;877:50-60.
18. Stokker GE. Hoffman WE. Alberts AW. et al: 3-hydroxv-3-methylglutaryl-coenzyme A reductase inhibitors: I. Structural modifications of 5-substitutcd 35-dihydroxypentanoic acids and their lactone derivatives. J Med Chem 1985:28:347-358.
19. Kathawala FG: HMG-CoA reductase inhibitors: An exciting development in the treatment of hyperlipoproteinemia. Med Res Rev 1991: 11:121-146.
20. Hunninghake DB: HMGCoA reductase inhibitors. C'urr Opin Lipidol 1992;3:22-28.
21. Feussner G: HMG CoA reductase inhibitors. CurrOpin Lipidol 1994:5:59-68.
22. Grunler J. Ericsson J, Dallner G: Branch-point reactions in the biosynthesis of cholesterol, dol-iehol. ubiquinone and prcnvlatcd proteins. Biochim BiophysActa 1994;1212:259-277.
23. Goldstein JL. Brown MS: Regulation of the mevalonate pathway. Nature 1990:343:425-430.
24. Habenichl AJR. Glomset JA. Ross R: Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem 1980:255:5134-5140.
25. Bernini F. Didoni G. Bonfadini G. Bellosta S. Fumagalli R: Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis 1993: 104:19-26.
26. Maltese WA. Sheridan KM: Differentiation of neuroblastoma cells induced by an inhibitor of mevalonate synthesis: Relation of neurite outgrowth and acetylcholinesterase activity to changes in cell proliferation and blocked iso-prenoid synthesis. J Cell Physiol 1985:125: 540-558.
27. Corsini A. Mazzotti M. Raiteri M. Soma MR. Gabbiani G. Fumagalli R, Paoletti R: Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993:101:117-125.
28. Maltese WA: Posttranslalional modification of proteins by isoprenoids in mammalian cells. FASEBJ 1990:4:3319-3328.
29. Glomset JA. Gelb MH. Farnsworth CC': Prenyl proteins in eukaryotic cells: A new type of membrane anchor. TIBS 1990; 15:139-142.
30. Sincnskv M. Lutz RJ: The prenylation of proteins. Bioessavs 1992:14:25-31.
31. Casey PJ: Biochemistry of protein prenylation. J Lipid Res 1992:33:1731-1740.
32. Corsini A. Raiteri M, Soma MR. Bernini F. Fumagalli R. Paoletti R: Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-meth-ylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 1995;76(suppl 2):21A-28A.
33. Corsini A. Maggi FM. Catapano. AL: Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995:31:9-27.
34. Soma MR. Donetti E. Parolini C. Mazzini G. Ferrari C. Fumagalli R. Paoletti R: HMG-CoA reductase inhibitors: In vivo effects on carotid inlimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 1993:13:571-578.
35. Zhu BQ. Sicvcrs RE. Sun YP. Isenberg WM. Parmlev WW: Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits. J Cardiovasc Pharmacol 1992:19: 246-255.
36. Gellman J. Ezekowitz MD. Sarembock IJ. Az-rin MA. Nochomowitz LE. Lerner E. Hauden-schild CC: Effect of lovastatin on intimal hyperplasia after balloon angioplasty: A study in an athrosclcrotic hypercholesterolemic rabbit. J Am Coll Cardiol 1991:17:251-259.
37. Bocan TMA. Mazur MJ. Mueller SB. Brown EQ. Sliskovic DR. O'Brien PM. Cresweu MW. Lee H. Uhlendorf PD. Roth BD. Newton RS: Antiatherosclcrotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: A biochemical and morphological evaluation. Atherosclerosis 1994;111:127-142.
38. Corsini A. Raiteri M, Soma MR, Fumagalli R, Paoletti R: Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacol Res 1991:23:173-180.
39. Soma MR. Parolini C. Donetti E. Fumagalli R. Paoletti R: Inhibition of isoprenoid biosynthesis and arterial smooth muscle cell proliferation. J Cardiovasc Pharmacol 1995;25(suppl 4):S20-S24.
40. Ross R: The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol 1971;50:172-186.
41. Lowry OH. Rosebrough NJ. Farr AL. Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951:193:265-275.
42. Fisher RA, Yates F: Statistical Tables lor Biological. Agricultural and Medical Research. Edinburgh. Oliver & Boyd. 1953. p 60.
43. Naito M. Hayashi T. Kuzuya M. Funaki C, Asai K. Kuzuya F: Effects of fibrinogen and fibrin on the migration of vascular smooth muscle cells in vitro. Atherosclerosis 1990:83: 9-14
44. Corsini A. Quarato P. Raiteri M. Paubert-Bra-quet M, Nguyen G. Piquot S. Bourgain RH. Fumagalli R, Paoletti R: Effect of nifedipine-atenolol association on arterial myocyte migration and proliferation. Pharmacol Res 1993:27: 299-307.
45. Havel R. Eder H. Bragdon J: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955:34:1345-1354.
46. Goldstein JL. Ho YK. Basu SK. Brown MS: Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein producing massive cholesterol deposition. Proc Nall Acad Sci USA 1979:76: 333-337.
47. Booth RGF. Martin JF. Honey AC. Hassall DG. Beesley JE. Moncada S: Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis 1989;76:257-268.
48. Schwartz CJ, Valcnte AJ, Sprague EA: A modern view of atherogenesis. Am J Cardiol 1993: 7L9B-I4B.
49. Cleland JGF. Krikler DM: Modification of atherosclerosis by agents that do not lower cholesterol. Br Heart J 1993:69:S54-S62.
50. Ip JH. Fuster V. Badimon L. Badimon J. Taub-man MB. Chcsebro JH: Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990:15:1667-1687.
51. Chen HW: Role of cholesterol metabolism in cell growth. Fed Proc 1984:43:126-130.
52. Casey PJ. Moomaw JF. Zhang FL. Higgins JB. Thissen JA: Prenylation and G protein signaling; in Recent Progress in Hormone Research. New York, Academic Press. 1994, pp 215-238.
53. Farnsworth CC. Gelb MH, Glomset JA: Identification of gcranyigeraniol-modified proteins in HeLa cells. Science 1990:247:320-322.
54. Farnsworth CC. Wolda SL. Gelb MH. Glomset JA: Human lamin B contains a famcsylatcd cysteine residue. J Biol Chem 1989:264: 20422-20429.
55. Casey PJ. Solsky PA. Der C J. Buss JE:p2lrasis modified by a farncsvl isoprenoid. Proc Nalt Acad Sci USA 1989:86:8323-8327.
56. Glomset JA. Farnsworth CC: Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Ann Rev Cell Biol 1994:10:181-205.
57. Scotl W: Hydrophilicity and the differential pharmacology of pravastatin; in Wood C (ed): Lipid management: Pravastatin and the differential pharmacology of HMG-CoA reductase inhibitors. London Round Table Series. Royal Society of Medicine Service. 1990. No 16, pp 17-25.
58. Miller MJ. Kuntz RE. Friedrich SP. Leidig C.A, Fishman RF. Schnitt SJ. Bairn DS. Safian RD: Frequency and consequences of intimal hyperplasia in specimens retrieved by directional atherectomy of native primary coronary artery stenoses and subsequent restenoses. Am J Cardiol 1993;71:652-658.
59. Isncr JM. Kearney M, Bauters C. Leclerc G. Nikol S, Pickering JG. Riessen R. Weir L: Use of human tissue specimens obtained by directional atherectomy to study restenosis. Trends Cardiovasc Med 1994;4:213-221.
60. O’Brien ER. Alpcrs CE. Stewart DK, Ferguson M, Tran N, Gordon D. Benditl EP. Hinohara T. Simpson JB, Schwartz SM: Proliferation in primary and rcstenotic coronary atherectomy tissue: Implications for antiproliferative therapy. CircRes 1993:73:223-231.
61. Katsuda S. Coltrera MD. Ross R. Gown AM: I luman atherosclerosis. IV. Immunocytochem-ical analysis of cell activation and proliferation in lesions of voung adults. Am J Pathol 1993: 142:1787-1793.
62. Pickering JG, Weir L. Jckanowski J. Kearney MA. Isncr JM: Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J Clin Invest 1993:91:1469-1480.
63. Gordon D. Reidv MA. Benditt EP, Schwartz SM: Cell proliferation in human coronary arteries. Proc Natl Acad Sci USA 1990:87:4600-4604.
64. Jackson CL. Schwartz SM: Pharmacology of smooth muscle cell replication. Hypertension 1992;20:713-736.
65. Wcintraub WS. Boccuzzi SJ. Klein JL. Kosins-ki AJ, King SB. III, Ivanhoe R. Cedarholm JC. Stillabowcr ME. Talley JD, DeMaio SJ. O'Neill WW, Frazier JE. II, Cohen-Bcrnslein CL, Robbins DC. Brown CL. III, Alexander RW: Lack of effect of Iovastatin on restenosis after coronary angioplasty. N Engl J Med 1994:331: 1331-1337.
66. Duggan DE. Chen IW. Bayne WF. Halpin RA. Duncan CA, Schwartz MS. Stubbs RJ. Vickers S: The physiological disposition of Iovastatin. Drug Metab Dispos 1989; 17:166-173.
67. Pentikainen P, Saraheimo M. Schwartz J. Amin R, Schwartz M. Brunner-Ferber F, Rogers J: Comparative pharmacokinetics of lovas-latin. simvastatin and pravastatin in humans. J Clin Pharmacol 1992:32:136-140.
68. Dain JG. Fu E. Gorski J, Nicolctti J, Scallcn TJ: Biotransformation of fluvastalin sodium in humans. Drug Metab Dispos 1993:21:567-572.
69. Foley DP. Bonnier H. Jackson G. Macaya C, Shepherd J, Vrolix M. Scrruys PW: Prevention of restenosis after coronary balloon angioplasty: Rationale and design of the Fluvastalin Angioplasty Restenosis (FLARE) Trial. Am J Cardiol 1994:73(suppl 14):50D-61D.
70. O’Brien ER. Schwartz SM: Update on the biology and clinical study of restenosis. Trends Cardiovasc Med 1994:4:169-178.
71. Steinberg D. Parthasarathy S. Carcw T. Khoo J. Witztum J: Beyond cholesterol: Modifications of low-density lipoprotein that increase its athcrogenicity. N Engl J Med I989;320: 915-924.
72. Hciaecke J W: Cellular mechanisms for the oxidative modification of lipoprotein implications for atherogenesis. Coron Artery Dis 1994:5: 205-210.
73. Witztum JL. Steinberg D: Role of oxidized low-density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-1792.
74. Kodama T. Reddy P. Kishimoto C. Krieger M: Purification and characterization of a bovine acetyl low density lipoprotein receptor. Proc Natl Acad Sci USA 1988:85:9238-9242.
75. Brown MS. Goldstein JL: Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Ann Rev Biochem 1983:52:223-261.
76. Giroux I.M. Davignon J. Naruzewicz M: Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993:1165:335-338.
77. Aviram M. Dankner G. Cogan U. Hochgraf E. Brook JG: Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies. Metabolism 1992:41:229-235.